A new paper in JACC: Advances delves into the factors that may affect implementation of a polypill for heart failure with reduced ejection fraction (HFrEF)—assuming one proves safe and effective—and outlines strategies for an eventual rollout. This exercise “just reinforces the idea, in addition to previous data showing therapeutic inertia and reluctance to use other single-pill combination therapies for cardiovascular diseases, that we need to plan in advance.
Getting Ready for a Heart Failure Polypill, Well Before the Data Are In
View Content